Prestige Consumer Healthcare completed the acquisition of Australian therapeutic skin care company LaCorium Health for approximately $150 million in cash on July 1, 2026. LaCorium, known for brands like Dermal Therapy and Flexitol, generates about $40 million in annual revenue and is expected to contribute $12 million in EBITDA after integration. Prestige also priced a $400 million senior notes offering at 6.25% due 2034, intending to use proceeds to redeem existing debt. The company will report its first quarter fiscal 2027 earnings on August 6, 2026.
The 32nd Global Family Office Investment Summit in Lake Como gathered over 200 family office leaders, investors, and entrepreneurs from 27 countries to discuss emerging trends in AI, private equity, healthcare innovation, and global investment opport...
Bath & Body Works introduced Fruit Fusion, a new body care franchise featuring fruit-inspired scents and hydrating formulas, available in the U.S. and Canada starting July 6, 2026. Actress Hilary Duff serves as the brand ambassador and creative partn...
GuideAI Health Corp. has appointed Dr. James F. Benenati, a leading interventional radiologist, to its Advisory Board following FDA 510(k) clearance of its AI software, VascularAssist Occlusion Triage (VAOT). VAOT is designed to help radiologists pri...
Diginex Limited has agreed with Resulticks to extend the deadline for their acquisition deal to July 31, 2026, after securing firm funding intent from private investors. The company does not plan to seek public funding and expects this to be the fina...
Rogers Communications has agreed to buy the remaining 25% stake in Maple Leaf Sports & Entertainment (MLSE) from Kilmer Sports for C$4.35 billion, making Rogers the sole owner. This move aims to strengthen Rogers' position in Canadian sports and ente...
